xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

551

PATEL et al.

TABLE IX-3 Evidence for CRSwNP-related olfactory loss management with oral corticosteroid therapy Study Year LOE Study design Study groups Clinical end point

Conclusions

Compared with placebo, the prednisone group demonstrated significantly greater improvements in VAS and butanol threshold tests at week 2 Compared with placebo groups, the oral steroid groups demonstrated significant improvement in both subjective and objective olfactory outcomes Compared with baseline, only the oral prednisone group demonstrated significant improvement at week 2 andweek 12 Compared with baseline, only the oral prednisone group demonstrated significant improvement in subjective symptom score at week 12 Compared with baseline, neither group demonstrated significant improvement Compared with placebo, the oral prednisolone group demonstrated significantly greater mean improvement in VAS (week 2 only) and PST (week 2 and week 10)

VAS (0–10) BTT Data collection points: week2

Ecevit

2015

2

RCT

CRSwNP (N = 22) Oral prednisolone 60 mg × 7days followed by taper Placebo

et al 1376

Banglawala et al 184

2014

1

Systematic

CRSwNP (N = 419) 5RCTswith follow-up ranging 12 to 48 weeks

Subjective olfactory outcomes Objective olfactory outcomes

reviewand meta-analysis

Alobid

BAST-24 Data collection points: week 2 and week 12

2014

2

RCT

CRSwNP (N = 92) Oral prednisone 30 mg taper × 2week + budesonide NS 400 μ g twice daily × 12weeks No treatment (n = 22) CRSwNP (N = 114) Oral prednisone 50 mg once daily × 2 weeks followed by MFNS200 μ g twice daily × 10 weeks Placebo once daily × 2 weeks followed by MF NS spray 200 μ g twice daily × 10weeks CRSwNP (N = 62) Oral prednisone 30 mg taper × 2weeks + budesonide NS 400 μ g twice daily × 12weeks (n = 46) No treatment (n = 16) CRSwNP (N = 60) Oral prednisolone 25 mg once daily × 2 weeks + FPnasal drops 400 μ g twice daily × 8weeks + FPNS × 18weeks (n = 30) Placebo tablets × 2 weeks + FPnasal drops 400 μ g twice daily × 8weeks + FPNS × 18weeks (n = 30)

et al 150

Kirtsreesakul et al 1377

2012

2

RCT

Subjective symptom score (0–3) Data collection points: week 12

Alobid

Subjective symptom score (0–3) Data collection points: week 2 and week 12

2012

2

RCT

et al 1378

Vaidyanathan et al 1379

2011

2

RCT

VAS (0–100) PST(0–3) Data collection points:

week 2, week 10, week 28

(Continues)